Alejandra, a woman in her 20s with polycystic ovary syndrome (PCOS), has been using a GLP‑1 for almost three years. She notices that more men approach her now, yet she worries whether they are attracted to her appearance or to her personality. She describes feeling insecure on dates, wondering if the interest is genuine or just a reaction to her new size.

Both women agree that the surge in attention is paired with new forms of stigma. Some men label GLP‑1 users as “lazy” or call the medication a “shortcut,” and these comments can be hurtful. Alejandra even recounts having to correct a date who used those terms, turning the conversation into an education about PCOS and the medication.

Academic research supports their experiences. A 2022 study published in the journal Stigma and Health found that heterosexual participants and gay men showed stronger weight bias when choosing dating partners, indicating that even after weight loss, societal preferences can remain biased. This suggests that “skinny privilege” does not erase deep‑rooted stereotypes.

The stories of Lipovsky and Alejandra show that GLP‑1‑induced weight loss can open doors in the dating scene, but it also brings fresh insecurities and judgment. Understanding both sides helps anyone on the medication to navigate relationships with realistic expectations.